V. Craig Jordan

Q: What Schools Are Affiliated With V. Craig Jordan

V. Craig Jordan is affiliated with the following schools: McGill University, University of Texas at Austin, Northwestern University , MD Anderson Cancer Center, University of Leeds, Georgetown University, University of New Zealand

V. Craig Jordan's AcademicInfluence.com Rankings

V. Craig Jordan

Medical

#141

World Rank

#218

Historical Rank

#71

USA Rank

Pharmacology

#17

World Rank

#23

Historical Rank

#10

USA Rank

medical Degrees

Download Badge

Medical

Why Is V. Craig Jordan Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Virgil Craig Jordan, , is a scientist with American and British citizenship specializing in drugs for breast cancer treatment and prevention. Currently, he is Professor of Breast Medical Oncology, and Professor of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. More recently his work has branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator . Currently, he plans to develop a new Hormone Replacement Therapy for post-menopausal women that prevents breast cancer and does not increase the risk of breast cancer.

(See a Problem?)

V. Craig Jordan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. (1999) (1638)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006) (1594)
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. (1992) (1132)
The pharmacology and clinical uses of tamoxifen. (1984) (879)
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial (2000) (746)
Basic guide to the mechanisms of antiestrogen action. (1998) (731)
Tamoxifen: a most unlikely pioneering medicine (2003) (683)
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial (2004) (647)
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer (2010) (594)
International Union of Pharmacology. LXIV. Estrogen Receptors (2006) (531)
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. (1977) (511)
The estrogen receptor: a model for molecular medicine. (2003) (486)
Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. (1988) (459)
Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. (1990) (456)
Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. (1988) (448)
MCF-7: the first hormone-responsive breast cancer cell line. (1997) (426)
Biochemical pharmacology of antiestrogen action. (1984) (421)
Endocrine pharmacology of antiestrogens as antitumor agents. (1990) (404)
Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. (1976) (396)
Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. (1991) (395)
Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. (1987) (390)
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. (2003) (377)
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. (2003) (356)
Selective estrogen receptor modulation: concept and consequences in cancer. (2004) (314)
Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. (2007) (305)
Most Plastic Products Release Estrogenic Chemicals: A Potential Health Problem That Can Be Solved (2011) (299)
Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer (2007) (297)
Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells. (1994) (296)
The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice (2013) (294)
Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. (1990) (292)
Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. (1996) (290)
Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer (2006) (290)
The biological role of estrogen receptors α and β in cancer (2004) (287)
Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. (2005) (283)
Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. (1992) (279)
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward (2006) (272)
Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. (1991) (269)
Estrogen receptors as therapeutic targets in breast cancer. (2006) (269)
Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. (1989) (268)
A current view of tamoxifen for the treatment and prevention of breast cancer (1993) (266)
Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? (2009) (248)
Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. (2005) (241)
Tamoxifen, raloxifene, and the prevention of breast cancer. (1999) (234)
The Small Heat Shock Protein αB-crystallin Is a Novel Inhibitor of TRAIL-induced Apoptosis That Suppresses the Activation of Caspase-3* (2005) (230)
Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. (1980) (226)
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. (2012) (223)
The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. (2010) (214)
Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. (2000) (211)
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. (1992) (209)
Selective estrogen receptor modulators and phytoestrogens. (2008) (199)
Effects of anti-estrogens on bone in castrated and intact female rats (1987) (199)
Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. (1975) (193)
The biological role of estrogen receptors alpha and beta in cancer. (2004) (184)
Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics (2012) (179)
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations (2013) (176)
Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. (2001) (172)
Tamoxifen: catalyst for the change to targeted therapy. (2008) (171)
Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. (1987) (167)
Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. (1988) (161)
Estrogen-related receptors as emerging targets in cancer and metabolic disorders. (2006) (161)
Selective estrogen receptor modulation: a personal perspective. (2001) (160)
Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. (1991) (155)
Pharmacology of tamoxifen in laboratory animals. (1980) (153)
New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer (2007) (152)
Chemoprevention of breast cancer with selective oestrogen-receptor modulators (2007) (151)
Estrogenic activity of phenol red (1988) (150)
Species-specific pharmacology of antiestrogens: role of metabolism. (1987) (149)
Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time (2011) (148)
Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. (1991) (148)
Early breast cancer (2009) (147)
Tamoxifen as an anti-tumour agent: effect on oestrogen binding. (1976) (146)
Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells (2009) (145)
3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha. (2006) (144)
Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. (1990) (143)
Chemoprevention of breast cancer: a model for change. (2002) (142)
Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance (1982) (141)
An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. (1983) (141)
Apoptotic Action of 17β-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo (2003) (140)
Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. (1987) (139)
Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. (1987) (137)
Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. (2003) (134)
The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. (1998) (132)
Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. (2002) (132)
An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol (1992) (131)
Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat (1977) (131)
A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. (1996) (130)
Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. (1992) (129)
Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal (2005) (129)
Clinical potential of new antiestrogens. (1997) (128)
Structure-activity relationships of estrogens. (1985) (127)
Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. (2014) (127)
Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. (1990) (127)
Nonsteroidal antiestrogens: their biological effects and potential mechanisms of action. (1978) (126)
Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. (1988) (126)
The effect of estrogen and progesterone on uterine prostaglandin biosynthesis in the ovariectomized rat. (1975) (124)
Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. (1989) (124)
Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. (1995) (123)
Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. (2000) (123)
The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. (2014) (118)
The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. (2002) (117)
Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines (1994) (116)
243. Antitumour activity of the antiestrogen ICI 46,474 (Tamoxifen) in the dimethylbenzanthracene (DMBA)—induced rat mammary carcinoma model (1974) (115)
Selective oestrogen receptor modulation: molecular pharmacology for the millennium. (1999) (115)
Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. (1976) (114)
Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER α (2003) (114)
Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. (2009) (112)
EVIDENCE FOR THE METABOLIC ACTIVATION OF NON‐STEROIDAL ANTIOESTROGENS: A STUDY OF STRUCTURE‐ACTIVITY RELATIONSHIPS (1980) (112)
Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor (1997) (112)
Stimulation of breast cancer cellsin vitro by the environmental estrogen enterolactone and the phytoestrogen equol (1987) (111)
Estrogen-Related Receptor α1 Transcriptional Activities Are Regulated in Part via the ErbB2/HER2 Signaling Pathway (2007) (109)
The Selective Estrogen Receptor Modulator Bazedoxifene Inhibits Hormone-Independent Breast Cancer Cell Growth and Down-Regulates Estrogen Receptor α and Cyclin D1 (2011) (106)
Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. (1983) (105)
The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain (2004) (104)
The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death? (2008) (103)
SERMs: meeting the promise of multifunctional medicines. (2007) (103)
Geometric isomers of substituted triphenylethylenes and antiestrogen action. (1981) (103)
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. (2006) (103)
Gynecologic effects of tamoxifen and the association with endometrial carcinoma (1995) (102)
Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. (1993) (102)
An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. (1995) (101)
The role of tamoxifen in the treatment and prevention of breast cancer. (1992) (101)
A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. (1985) (100)
Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. (1989) (97)
Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response. (1976) (96)
Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. (1993) (96)
Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. (1990) (95)
Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus (1982) (95)
Peroxisome Proliferator-activated Receptor γ Agonists Promote TRAIL-induced Apoptosis by Reducing Survivin Levels via Cyclin D3 Repression and Cell Cycle Arrest* (2005) (94)
A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. (1995) (94)
Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells (2013) (94)
Dose-related effects of non-steroidal antioestrogens nad oestrogens on the measurement of cytoplasmic oestrogen receptors in the rat and mouse uterus. (1978) (92)
Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. (2000) (92)
Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. (1998) (91)
A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. (2009) (90)
Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor. (1984) (90)
Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. (2001) (88)
Should clinicians be concerned about the carcinogenic potential of tamoxifen? (1994) (87)
Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. (1983) (87)
SERMs for the treatment and prevention of breast cancer (2007) (86)
“Studies on the estrogen receptor in breast cancer” — 20 years as a target for the treatment and prevention of cancer (2004) (86)
Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications (1983) (86)
The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole (1988) (85)
Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. (2001) (84)
Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. (1996) (84)
A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. (1993) (84)
A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. (1996) (84)
Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model. (1987) (82)
The strategic use of antiestrogens to control the development and growth of breast cancer. (1992) (82)
Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. (1993) (82)
Tamoxifen: the herald of a new era of preventive therapeutics. (1997) (80)
Steroid receptors and their role in the biology and control of breast cancer growth. (2006) (80)
Selective oestrogen receptor modulation (1999) (80)
High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. (1989) (80)
Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations. (1988) (79)
Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines (2000) (79)
Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. (1992) (78)
Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. (1992) (78)
Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. (1990) (77)
c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. (2013) (76)
Determination of tamoxifen and metabolites in human serum by high-performance liquid chromatography with post-column fluorescence activation. (1983) (76)
Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. (1997) (76)
Molecular mechanisms of antiestrogen action in breast cancer (2004) (76)
Tamoxifen Regulates Cell Fate Through Mitochondrial Estrogen Receptor Beta in Breast Cancer (2012) (75)
Tamoxifen as an anti-tumour agent: role of oestradiol and prolactin. (1976) (75)
Estrogen/Antiestrogen Action and Breast Cancer Therapy (1986) (75)
Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. (1998) (75)
Aspirin Sensitizes Cancer Cells to TRAIL–Induced Apoptosis by Reducing Survivin Levels (2008) (74)
The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. (1998) (73)
Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells. (2008) (73)
Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro. (1984) (73)
Molecular classification of estrogens. (2001) (73)
Effects of low dose tamoxifen on normal breast tissue from premenopausal women. (2003) (73)
Characteristics of salivary profiles of oestradiol and progesterone in premenopausal women. (2005) (73)
Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. (1983) (72)
Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. (1989) (72)
Modulation of Estrogen Receptor α Function and Stability by Tamoxifen and a Critical Amino Acid (Asp-538) in Helix 12* (2003) (71)
A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. (1997) (71)
Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis (2008) (71)
Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. (1995) (71)
Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells (2010) (71)
Overview from the International Conference on Long-Term Tamoxifen Therapy for Breast Cancer. (1992) (70)
Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A “New” Biology of Estrogen-induced Apoptosis (2011) (70)
Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. (1994) (70)
Progress in endocrine approaches to the treatment and prevention of breast cancer. (2011) (70)
Structure-Function Relationships of the Raloxifene-Estrogen Receptor-α Complex for Regulating Transforming Growth Factor-α Expression in Breast Cancer Cells* (2002) (69)
Long-Term Tamoxifen Treatment for Breast Cancer (1994) (68)
Endometrial carcinoma and tamoxifen: clearing up a controversy. (1995) (68)
Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? (2009) (68)
Binding of [3h]tamoxifen in rat uterine cytosols: A comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis (1977) (68)
Determination of estrogen receptor in breast cancer using monoclonal antibody technology: results of a multicenter study in the United States. (1986) (68)
Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations (2012) (68)
Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. (2002) (68)
Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. (2003) (67)
MICoA, a Novel Metastasis-associated Protein 1 (MTA1) Interacting Protein Coactivator, Regulates Estrogen Receptor-α Transactivation Functions* (2003) (67)
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. (1999) (66)
Tamoxifen and contralateral breast cancer. (1999) (66)
Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). (2005) (66)
Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. (2001) (66)
The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. (1999) (64)
Aryl hydrocarbon receptor agonists directly activate estrogen receptor α in MCF-7 breast cancer cells (2006) (63)
Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2 (2004) (63)
Growth Stimulation and Differential Regulation of Transforming Growth Factor-β1 (TGFβ1), TGFβ2, and TGFβ3 Messenger RNA Levels by Norethindrone in MCF-7 Human Breast Cancer Cells (1991) (63)
The estrogenic activity of synthetic progestins used in oral contraceptives (1993) (63)
Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. (2009) (62)
Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. (2008) (62)
Tamoxifen, raloxifene and the prevention of breast cancer. (2002) (62)
Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. (1995) (61)
The Past, Present, and Future of Selective Estrogen Receptor Modulation (2001) (61)
Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast. (1988) (61)
Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. (2002) (61)
Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER. (1994) (59)
Considerations into the mechanism of estrogen-stimulated uterine prostaglandin synthesis. (1976) (59)
Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells (2003) (59)
Modulation of rat uterine steroid hormone receptors by estrogen and antiestrogen. (1980) (58)
Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. (1989) (58)
Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure. (1984) (57)
Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth. (1989) (57)
Prolonged antioestrogenic activity of ICI 46, 474 in the ovariectomized mouse. (1975) (57)
Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen (2007) (57)
Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. (1990) (57)
Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer. (2001) (56)
Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. (1993) (56)
A Risk-Benefit Assessment of Tamoxifen Therapy (1993) (55)
Effect of oestradiol benzoate, tamoxifen and monohydroxytamoxifen on immature rat uterine progesterone receptor synthesis and endometrial cell division. (1979) (55)
Treatment of estrogen deficiency symptoms in women surviving breast cancer. The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer Center and Woman's Place. (1999) (54)
Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts. (2001) (54)
Designer estrogens. (1998) (54)
Oestrogenic and antioestrogenic actions in a series of triphenylbut‐1‐enes: modulation of prolactin synthesis in vitro (1986) (54)
Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. (2000) (53)
Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. (2002) (53)
Long-term adjuvant tamoxifen therapy for breast cancer (1990) (53)
Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. (1988) (52)
Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity (1995) (51)
Metabolism of tamoxifen and its uterotrophic activity. (1985) (51)
In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer (2002) (51)
Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells (1993) (51)
Inhibition of oestrogen-stimulated prolactin release by anti-oestrogens. (1975) (51)
Breast Cancer Cell Apoptosis with Phytoestrogens Is Dependent on an Estrogen-Deprived State (2014) (50)
Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver. (1995) (50)
Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy (2005) (50)
Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. (1987) (49)
Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro. (1988) (49)
Regulation of the levels of three transforming growth factor β mRNAs by estrogen and their effects on the proliferation of human breast cancer cells (1993) (48)
5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of tamoxifen in breast cancer cells. (2013) (48)
Subcellular effects of monohydroxytamoxifen in the rat uterus: steroid receptors and mitosis. (1980) (48)
Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. (1989) (48)
Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years (1988) (48)
The Science of Selective Estrogen Receptor Modulators: Concept to Clinical Practice (2006) (47)
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial (2006) (46)
Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells (2018) (46)
Tamoxifen and tumorigenicity: a predictable concern. (1995) (46)
Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. (1995) (46)
Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. (2014) (45)
The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer (1997) (45)
Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women's health initiative study. (2014) (45)
Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen. (1989) (44)
Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse. (1991) (44)
Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice (2004) (44)
Regulation of prolactin synthesis in vitro by estrogenic and antiestrogenic derivatives of estradiol and estrone. (1989) (44)
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen. (2010) (44)
A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. (2014) (43)
Binding of [3H]monohydroxytamoxifen by immature rat tissues in vivo. (1982) (43)
The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: possible role in antiestrogen failure. (1989) (43)
Tamoxifen: a personal retrospective. (2000) (43)
Reliability of steroid hormone receptor assays: an international study. (1983) (42)
Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. (2003) (42)
Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus. (1985) (42)
Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. (2005) (42)
Control of the estrogen-like actions of the tamoxifen–estrogen receptor complex by the surface amino acid at position 351 (2001) (42)
Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers (2013) (42)
The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. (2005) (41)
MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. (2005) (41)
Tamoxifen for breast cancer prevention (1995) (41)
Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. (1991) (41)
Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. (2007) (41)
Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran with estrogen receptor alpha. (2004) (40)
Tamoxifen to raloxifene and beyond. (2001) (40)
Metabolism of steroid-modifying anticancer agents. (1988) (40)
Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. (2002) (40)
Molecular mechanisms of resistance to tamoxifen therapy in breast cancer. (1993) (40)
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. (1998) (39)
A mechanism of drug resistance to tamoxifen in breast cancer (2002) (39)
Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines. (2012) (39)
Obesity and male breast cancer: provocative parallels? (2015) (39)
Optimizing the antihormonal treatment and prevention of breast cancer (2007) (38)
Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. (2010) (38)
Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen. (1996) (38)
Proteomic Analysis of Pathways Involved in Estrogen-Induced Growth and Apoptosis of Breast Cancer Cells (2011) (38)
Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus. (1985) (38)
Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality (2013) (38)
The effect of tamoxifen and two of its non-isomerizable fixed-ring analogs on multistage rat hepatocarcinogenesis. (1996) (38)
Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade. (2002) (37)
A prospective study of variability in mammographic density during the menstrual cycle (2010) (37)
Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor. (1983) (37)
Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy. (2014) (37)
Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators. (2015) (36)
Alternate antiestrogens and approaches to the prevention of breast cancer (1995) (36)
Effect of non-steroidal anti-oestrogens on the concentration of rat uterine progesterone receptors. (1978) (36)
Acceptance of tamoxifen chemoprevention by physicians and women at risk (2004) (35)
Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. (1996) (35)
Targeted anti-estrogens to treat and prevent diseases in women. (1996) (35)
Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer. (1989) (35)
The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. (2011) (35)
Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations (2014) (35)
Targeted Antiestrogens to Prevent Breast Cancer (1999) (35)
Targeting oestrogen to kill the cancer but not the patient (2004) (35)
New insights into acquired endocrine resistance of breast cancer (2019) (34)
Long-term tamoxifen adjuvant therapy in node-positive breast cancer: A metabolic and pilot clinical study (1984) (34)
Is tamoxifen the Rosetta stone for breast cancer? (2003) (34)
Activity of the antioestrogen trioxifene against N-Nitrosomethylurea-induced rat mammary carcinomas. (1981) (34)
Development and Therapeutic Options for the Treatment of Raloxifene-Stimulated Breast Cancer in Athymic Mice (2006) (34)
4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiatedin vitro (2004) (33)
Tamoxifen‐stimulated Growth of Human Endometrial Carcinoma (1991) (33)
Subcellular compartmentalization of MCF-7 estrogen receptor synthesis and degradation (1993) (33)
Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. (2006) (33)
Steroid hormone receptors in adenocarcinoma of the endometrium. (1980) (33)
Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement (2015) (32)
Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes. (1988) (32)
Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor α (2002) (32)
Tamoxifen treatment for breast cancer: concept to gold standard. (1997) (32)
Hormonal treatment of advanced breast cancer. (1995) (31)
EGF activates highly selective estrogen-responsive reporter plasmids by an ER-independent pathway (2000) (31)
Tamoxifen treatment for breast cancer: Concept to gold standard (1997) (31)
Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial. (2006) (31)
Selective oestrogen receptor modulation: molecular pharmacology for the millennium. (1999) (30)
Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. (2006) (29)
Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes (2014) (29)
Steroid Hormone Receptors and Human Breast Cancer (1985) (29)
Laboratory models of breast cancer to aid the elucidation of antiestrogen action (1987) (29)
Growth factor regulation by tamoxifen is demonstrated in patients with breast cancer (1993) (29)
Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapy. (1983) (29)
Long-term adjuvant tamoxifen study: Clinical update (1987) (29)
Mechanisms underlying differential response to estrogen-induced apoptosis in long-term estrogen-deprived breast cancer cells (2014) (29)
Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. (2008) (29)
The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis. (2009) (28)
The secrets of selective estrogen receptor modulation: cell-specific coregulation. (2002) (28)
Role of the progesterone receptor (PR) in susceptibility of mouse mammary gland to 7,12-dimethylbenz[a]anthracene-induced hormone-independent preneoplastic lesions in vitro. (2002) (28)
Rat uterine growth and induction of progesterone receptor without estrogen receptor translocation. (1985) (28)
Prolactin-Induced Protein (PIP) Regulates Proliferation of Luminal A Type Breast Cancer Cells in an Estrogen-Independent Manner (2013) (28)
Cloning and characterization of a 77-kDa oestrogen receptor isolated from a human breast cancer cell line. (1997) (28)
Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene (2011) (27)
The conformation of the estrogen receptor directs estrogen-induced apoptosis in breast cancer: a hypothesis (2011) (27)
The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-Induced Tumor Cell Death (2004) (27)
Raloxifene as a multifunctional medicine? (1999) (27)
Bioluminescence imaging for assessment and normalization in transfected cell arrays (2007) (27)
The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy (2015) (27)
What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? A personal perspective. (1995) (27)
Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice. (2001) (27)
Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. (2002) (27)
Integration of Downstream Signals of Insulin-like Growth Factor-1 Receptor by Endoplasmic Reticulum Stress for Estrogen-Induced Growth or Apoptosis in Breast Cancer Cells (2015) (27)
Laboratory models of breast cancer to aid the elucidation of antiestrogen action. (1987) (27)
Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. (2010) (26)
Estrogen Receptor Expression and Sensitivity to Paclitaxel in Breast Cancer (2004) (26)
Oestradiol stimulates growth of oestrogen receptor-negative MDA-MB-231 breast cancer cells in immunodeficient mice by reducing cell loss. (1994) (26)
In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo. (1988) (26)
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer (1992) (26)
Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism (1995) (26)
Should adjuvant tamoxifen therapy be stopped at 5 years? (1996) (26)
Estrogen receptor distribution in enucleated breast cancer cell lines. (1988) (25)
Defining the Conformation of the Estrogen Receptor Complex That Controls Estrogen-Induced Apoptosis in Breast Cancer (2014) (25)
The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators (2014) (25)
Novel agents to modulate oestrogen action. (2000) (25)
Non-steroidal antioestrogens : molecular pharmacology and antitumour activity (1981) (24)
Changing role of the oestrogen receptor in the life and death of breast cancer cells. (2003) (24)
Structural components necessary for the antiestrogenic activity of tamoxifen. (1989) (24)
Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death (2014) (24)
Tamoxifen-induced increase in the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry. (1993) (24)
Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats (2004) (23)
Estrogen receptor-mediated direct and indirect antitumor effects of tamoxifen. (1990) (23)
Chemoprevention of Breast Cancer: Current and Future Prospects (2002) (23)
Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. (2007) (23)
Anti-oestrogen action in experimental breast cancer. (1980) (23)
Differences in the rate of oestrogen‐induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol (2014) (22)
The Selective Estrogen Receptor Modulator Bazedoxifene Inhibits Hormone-Independent Breast Cancer Cell Growth and Down-Regulates Estrogen Receptor and Cyclin D 1 (2011) (22)
Strategies for breast cancer therapy with antiestrogens. (1987) (22)
Hormonal therapy for breast cancer. An update. (1999) (22)
Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells (2018) (22)
Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices—Point (2007) (22)
Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing. (2001) (22)
Chemosuppression of breast cancer with long-term tamoxifen therapy. (1991) (22)
Detection of the 8 S oestrogen-binding component in human uterine endometrium during the menstrual cycle. (1975) (22)
Progress in the prevention of breast cancer: concept to reality (2000) (22)
A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labelling index in women with primary breast cancer. (2000) (21)
OESTROGENIC, ANTI‐OESTROGENIC AND FERTILITY EFFECTS OF SOME TRIPHENYLETHANES AND TRIPHENYLETHYLENES RELATED TO ETHAMOXYTRIPHETOL (MER 25) (1976) (21)
Avoiding the bad and enhancing the good of soy supplements in breast cancer. (2014) (21)
Risk factors and the prevention of breast cancer with tamoxifen. (1993) (21)
New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. (2009) (21)
In vitro study of the effect of raloxifene on lipid metabolism compared with tamoxifen. (2000) (21)
Binding of [3H] monohydroxytamoxifen in human breast carcinoma cytosols. (1981) (21)
Risks and benefits of tamoxifen therapy. (1997) (21)
Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation. (1988) (21)
Steroid and Prostaglandin Relations During the Menstrual Cycle (1977) (20)
Drug resistance to tamoxifen during breast cancer therapy (2004) (20)
Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction. (1998) (20)
Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer (2009) (20)
Long-term tamoxifen therapy for breast cancer. (1989) (20)
Emerging principles for the development of resistance to antihormonal therapy: Implications for the clinical utility of fulvestrant (2006) (20)
Rethinking Extended Adjuvant Antiestrogen Therapy to Increase Survivorship in Breast Cancer. (2018) (20)
Tamoxifen for the Treatment and Prevention of Breast Cancer (1999) (20)
Sensitivity and insensitivity of breast cancer to tamoxifen (1990) (20)
The inhibition of prolactin synthesis in GH3 rat pituitary tumor cells by monohydroxytamoxifen is associated with changes in the properties of the estrogen receptor. (1984) (20)
TAMOXIFEN AND ENDOMETRIAL CANCER (1989) (19)
THE BINDING OF [3H]‐OESTRADIOL‐17β IN THE IMMATURE RAT UTERUS DURING THE SEQUENTIAL ADMINISTRATION OF NONSTEROIDAL ANTI‐OESTROGENS (1979) (19)
An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor (1996) (19)
Pure antiestrogens as a new therapy for breast cancer. (1997) (19)
HYDROXYLATED ANTIOESTROGENS: NEW PHARMACOLOGICAL PROBES TO INVESTIGATE OESTROGEN AND ANTIOESTROGEN ACTION (1982) (18)
Inhibition of oestradiol binding to mouse uterine and vaginal oestrogen receptors by triphenylethylenes. (1975) (18)
PROPHYLACTIC TAMOXIFEN (1986) (18)
Estrogen receptor α mediated induction of the transforming growth factor α gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells (2001) (18)
Long-term tamoxifen therapy to control or to prevent breast cancer: laboratory concept to clinical trials. (1988) (18)
Influence of the Length and Positioning of the Antiestrogenic Side Chain of Endoxifen and 4-Hydroxytamoxifen on Gene Activation and Growth of Estrogen Receptor Positive Cancer Cells (2014) (18)
Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer (2018) (18)
Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells. (1998) (18)
50th ANNIVERSARY OF THE FIRST CLINICAL TRIAL WITH ICI 46,474 (TAMOXIFEN): THEN WHAT HAPPENED? (2020) (18)
Suppression of Nuclear Factor-κB by Glucocorticoid Receptor Blocks Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells (2019) (18)
Structural derivatives of tamoxifen and oestradiol 3-methyl ether as potential alkylating antioestrogens. (1981) (18)
The decreased influence of overall treatment time on the response of human breast tumor xenografts following prolongation of the potential doubling time (Tpot). (1995) (18)
Antiestrogens: clinical applications of pharmacology. (2000) (18)
Enhanced growth of an estrogen receptor-negative endometrial adenocarcinoma by estradiol in athymic mice. (1989) (18)
Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients. (2014) (17)
Estrogen receptor as a target for the prevention of breast cancer. (1999) (17)
Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer. (2016) (17)
An Overview of Considerations for the Testing of Tamoxifen as a Preventive for Breast Cancer (1995) (17)
A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers (2017) (17)
Tamoxifen Inhibits Lipoprotein Activity: In vivo and in vitro Studies (2000) (16)
Trastuzumab therapy for tamoxifen-stimulated endometrial cancer. (2005) (16)
Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells. (1993) (16)
Long-term adjuvant tamoxifen therapy for breast cancer: the prelude to prevention. (1990) (16)
The effect of reported prostaglandin synthetase inhibitors on estradiol-stimulated uterine prostaglandin biosynthesis in vivo in the ovariectomized rat. (1976) (16)
Molecular Mechanism for Breast Cancer Incidence in the Women's Health Initiative (2020) (15)
Laboratory models of hormone-dependent cancer (1982) (15)
Mutations of the estrogen receptor in endometrial carcinoma: evidence of an association with high tumor grade. (1996) (15)
Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells. (2014) (15)
Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women’s Health (2018) (15)
A Retrospective: On Clinical Studies with 5-Fluorouracil. (2016) (15)
Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer (2014) (15)
The only true antiestrogen is no estrogen (1990) (15)
Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM. (2019) (15)
How safe is tamoxifen? (1993) (15)
Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer (2020) (15)
Tamoxifen: too much of a good thing? (1999) (14)
Tamoxifen: Pioneering Medicine in Breast Cancer (2015) (14)
Growth stimulation and differential regulation of transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, and TGF beta 3 messenger RNA levels by norethindrone in MCF-7 human breast cancer cells. (1991) (14)
High affinity binding of anti-oestrogen to the chick liver nuclear oestrogen receptor. (1982) (14)
Effects of tamoxifen in relation to breast cancer. (1977) (14)
Beyond raloxifene for the prevention of osteoporosis and breast cancer (2007) (14)
Selective Estrogen Receptor Modulation (2001) (14)
The control of hormone-dependent breast cancer growth--are we talking about estrogen alone? (1988) (14)
Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. (1996) (14)
Molecular mechanisms and future uses of antiestrogens. (1997) (14)
Current controversies in breast cancer management. (1999) (14)
Hormonal strategies for breast cancer: a new focus on the estrogen receptor as a therapeutic target. (1992) (13)
Oestrogen receptors, growth factors and the control of breast cancer (2001) (13)
Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer (2016) (13)
TAMOXIFEN AND ENDOMETRIAL CANCER (1988) (13)
Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. (1998) (13)
An immobilized antiestrogen binds a specific uterine protein in addition to estrogen receptor proteins (1984) (13)
Preclinical studies with toremifene as an antitumor agent (1990) (13)
An appraisal of strategies to reduce the incidence of breast cancer (1993) (13)
Re: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol and the two faces of Janus: sex steroids as mediators of both cell proliferation and cell death. (2002) (13)
What do we know and what don't we know about tamoxifen in the human uterus (2004) (12)
Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer. (1999) (12)
Inhibition of oestradiol binding to oestrogen receptor proteins by a methyl-substituted analogue of tamoxifen. (1976) (12)
The biological action of cDNAs from mutated estrogen receptors transfected into breast cancer cells. (1995) (12)
Antiestrogen stimulated human endometrial cancer growth: laboratory and clinical considerations 1 1 Proceedings of the 13th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology “Recent Advances in Steroid Biochemistry & Molecular Biology” Monaco 25–28 May 1997. (1998) (12)
Hormone Therapy in Breast and Prostate Cancer (2002) (12)
Oestrogen Binding as a Predictive Test for DMBA-Induced Tumour Response to Tamoxifen Therapy (1976) (12)
Estrogen-Induced Apoptosis in Breast Cancers Is Phenocopied by Blocking Dephosphorylation of Eukaryotic Initiation Factor 2 Alpha (eIF2α) Protein (2019) (12)
Inhibition of hormone-dependent and independent breast cancer cell growthin vivo andin vitro with the antiestrogen toremifene and recombinant human interferon-α2 (1990) (12)
Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells. (2009) (12)
Breast Cancer Research and Treatment 2001 Reviewers (2004) (12)
Effects of antiestrogens on the induction of vitellogenin and its mRNA in Xenopus laevis. (1986) (12)
How is tamoxifen's action subverted? (2000) (12)
Antiestrogenic effect of trifluoperazine in mice. (1985) (12)
The modulation of estrogen-induced apoptosis as an interpretation of the women’s health initiative trials (2016) (12)
Selective estrogen-induced apoptosis in breast cancer (2014) (12)
Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story. (2013) (12)
Nuclear [3H]4-hydroxytamoxifen (4-OHTAM)- and [3H]estradiol (E2)-estrogen receptor complexes in the MCF-7 breast cancer and GH3 pituitary tumor cell lines (1984) (11)
Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells. (1992) (11)
Chemotherapy is antihormonal therapy--how much proof do oncologists need? (1998) (11)
Estrogens and antiestrogens : basic and clinical aspects (1997) (11)
The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells (2020) (11)
Oestrogens, Oestrogen Receptors and Breast Cancer (2003) (11)
Targeting antihormone resistance in breast cancer: a simple solution. (2003) (11)
Relation of steroids and prostaglandin at vaginal delivery and cesarean section (1975) (11)
Tamoxifen Prophylaxis: Prevention is Better Than Cure — Prevention is Cure? (1986) (10)
Tamoxifen and endometrial cancer: from experiment to patient. (1996) (10)
Deregulation of estrogen induced telomerase activity in tamoxifen-resistant breast cancer cells. (2005) (10)
The rise of raloxifene and the fall of invasive breast cancer. (2008) (10)
Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale. (2015) (10)
Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene. (1998) (10)
Managing Breast Cancer Risk (2003) (10)
Biochemical Evidence for the Exclusive Nuclear Localization of the Estrogen Receptor (1987) (10)
A therapeutic withdrawal can make a strategic advance. (1992) (10)
Tamoxifen for Breast Cancer Prevention (1995) (10)
A realistic assessment of the association between tamoxifen and endometrial cancer (1995) (9)
The antitumour activity of tamoxifen and monohydroxytamoxifen: a comparative study in the rat [proceedings]. (1978) (9)
Raloxifene for the treatment and prevention of breast cancer? (2001) (9)
A comparison, at the cellular and subcellular levels, of the effects of tamoxifen and oestradiol benzoate on the immature rat uterus [proceedings]. (1978) (9)
A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens (2004) (9)
PERK, Beyond an Unfolded Protein Response Sensor in Estrogen-Induced Apoptosis in Endocrine-Resistant Breast Cancer (2021) (9)
Targeted antiestrogens for the prevention of breast cancer. (1999) (9)
Structure-activity relationships for triphenylethylene antiestrogens on hepatic phase-I and phase-II enzyme expression. (1998) (9)
Tamoxifen and endometrial cancer: tamoxifen effects on the human female genital tract. (1997) (9)
MICoA , a Novel MTA 1 Interacting Protein Coactivator , Regulates Estrogen Receptor-alpha Transactivation Functions * (2003) (8)
Surgical Oncology Forum: Tamoxifen for the Prevention of Breast Cancer in the High-Risk Woman (2000) (8)
Antiestrogens and the reduction in circulating cholesterol. (1996) (8)
The mode of action of the antitumour agent GP 48,989 in the rat. (1979) (8)
Active immunization to luteinizing hormone releasing hormone to inhibit the induction of mammary tumors in the rat. (1988) (8)
Effect of chronic administration of mestranol, tamoxifen, and toremifene on hepatic ploidy in rats. (1998) (8)
Estrogen Action, Selective Estrogen Receptor Modulators and Women's Health:Progress and Promise (2013) (8)
How PERK kinase conveys stress signals to nuclear factor-κB to mediate estrogen-induced apoptosis in breast cancer cells? (2018) (8)
Role of tamoxifen in the long-term treatment and prevention of breast cancer. (1988) (8)
Interaction of [3H] estradiol — and [3H] monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody (1983) (8)
Inhibition of cell division and stimulation of progesterone receptor synthesis in rat oestrogen target tissues by non-steroidal antioestrogens. (1979) (8)
Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive (2018) (8)
Pak up your breast tumor--and grow! (2006) (8)
Antiestrogen Therapy for Breast Cancer (1988) (8)
Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer (2020) (8)
A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis? (2014) (8)
Problems with the progesterone receptor in practice? (2007) (8)
Potential of endogenous estrogen receptor β to influence the selective ER modulator ERβ complex (2005) (7)
Chemoprevention with Antiestrogens: The Beginning of the End for Breast Cancer (2001) (7)
Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells. (2001) (7)
Effects of angiogenesis inhibitor TNP-470 on tamoxifen-stimulated MCF-7 breast tumors in nude mice. (2000) (7)
Binding of [3H] monohydroxytamoxifen in ovarian carcinoma (1983) (7)
Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex. (2005) (7)
Estrogenic effects of phenolphthalein on human breast cancer cellsin vitro (1987) (7)
Medroxyprogesterone acetate and metastases: of mice and (wo)men. (2005) (7)
The Estrogen Receptor: A Logical Target for the Prevention of Breast Cancer with Antiestrogens (2004) (7)
Comparative antioestrogen action in experimental breast cancer. (1981) (7)
The current status of breast cancer chemoprevention: A star is born (2007) (6)
Relation of Steroids and Prostaglandin at Vaginal Delivery and Cesarean Section (1975) (6)
Human recombinant interferon-βSER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse (2004) (6)
Adjuvant antiestrogen therapy for breast cancer. Past, present, and future. (1990) (6)
Tamoxifen as the first successful targeted therapy in cancer: the gift that kept on giving (2014) (6)
Improving long-term adjuvant anti-oestrogenic therapy for breast cancer (2016) (6)
The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture (2019) (6)
Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer. (2015) (6)
The ups and downs of the estrogen receptor. (2003) (6)
Tamoxifen: From breast cancer therapy to the design of a postmenopausal prevention maintenance therapy (1997) (6)
Antiestrogen therapy for breast cancer: current strategies and future prospects. (1988) (6)
Estrogens and Antiestrogens (2003) (6)
Improvements in tumor targeting, survivorship, and chemoprevention pioneered by tamoxifen. A personal perspective. (2006) (6)
Meeting report: long-term antihormonal therapy for breast cancer. (1991) (6)
Effect of raloxifene on salivary sex steroid concentrations in premenopausal women. (2006) (6)
Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapy. (1997) (6)
Aromatase inhibitors that regulate estrogen target tissues selectively? (2004) (5)
Understanding the antiestrogenic actions of raloxifene and a mechanism of drug resistance to tamoxifen (1998) (5)
Angela M. Hartley Brodie (1934–2017) (2017) (5)
AN EMERGING PRINCIPLE: SELECTIVE NUCLEAR RECEPTOR MODULATORS (2013) (5)
Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy (1998) (5)
Therapeutic efficacy, side effects and the potential for tamoxifen to prevent breast cancer (1991) (5)
Characterization of a point mutation in the hormone binding domain of the estrogen receptor from an breast tumor. (1998) (5)
Four decades of discovery in breast cancer research and treatment--an interview with V. Craig Jordan. Interview by Marc Poirot. (2011) (5)
The Study of Letrozole Extension (SOLE) revisited. (2018) (5)
Endoxifen: The End, or Are We at the Beginning? (2017) (5)
Resistance to Antioestrogen Therapy: a Challenge for the Future (1989) (5)
Analysis of Tamoxifen and its Metabolites (1984) (5)
Tamoxifen-Failed Male Breast Cancer with a High Level of Circulating Estrogen: Report of a Case (2001) (4)
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. Part 2. Clinical Considerations and New Agents (2003) (4)
chromatin dynamics Differential DNase I hypersensitivity reveals factor-dependent Material Supplemental (2012) (4)
Models of hormone resistance in vitro and in vivo. (2006) (4)
Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team (2021) (4)
The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture (2019) (4)
Raloxifene stimulated endometrial cancer grown in athymic mice: Cross resistance with ICI182,780 and antitumor action of estradiol (2001) (4)
Optimisation of antioestrogen therapy: laboratory and clinical concepts (1989) (4)
Role for HER 2 / neu and HER 3 in fulvestrant-resistant breast cancer (2007) (4)
Long-term Adjuvant Tamoxifen Therapy and Decreases in Contralateral Breast Cancer. (2017) (4)
A Mutant Receptor as a Mechanism of Drug Resistance to Tamoxifen Treatment a (1995) (4)
A Novel Strategy to Improve Women’s Health: Selective Estrogen Receptor Modulators (2018) (4)
The duration of adjuvant tamoxifen therapy. (1998) (4)
2–39 Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene (2005) (4)
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. Part 1. Receptor Interactions (2003) (4)
Tamoxifen for Breast Cancer Prevention: Ready for Prime Time? (1998) (4)
Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer (2020) (4)
Introducing a new section to Breast Cancer Research: Endocrinology and hormone therapy (2003) (4)
Prolonged adjuvant tamoxifen: a beginning not the end. (1991) (4)
Evolution of estrogen action in breast cancer: From culprit to killer (2013) (4)
Drug resistance to tamoxifen: mutant estrogen receptors as a potential mechanism of tamoxifen-stimulated tumor growth (1995) (4)
Development of a new prevention maintenance therapy for postmenopausal women. (1999) (4)
After the menopause: tamoxifen and other new prevention maintenance therapies. (1997) (3)
The biological significance of the interaction of estrogen agonists and antagonists with the estrogen receptor. (1990) (3)
Effect of submandibular gland removal on carcinogen induced rat mammary tumors. (1987) (3)
The evolving role of endocrine therapy for treatment and prevention of breast cancer. (2001) (3)
A molecular strategy to control tamoxifen resistant breast cancer. (1992) (3)
Estrogen receptors in BRCA1-mutant breast cancer: now you see them, now you don't. (2007) (3)
Estrogen Receptor and the Unfolded Protein Response: Double-Edged Swords in Therapy for Estrogen Receptor-Positive Breast Cancer (2022) (3)
Antiestrogens: the past and the future. (2002) (3)
Tumor Targeting in Cancer Therapy (2002) (3)
Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently? (2017) (3)
A comparative study of electrophoretic mobilities of [3H]-estradiol and monohydroxytamoxifen binding components in the cytosols of human breast carcinomas and sera of healthy adult females. (1983) (3)
O-097. Action of oestrogens and their antagonists on target organs (1997) (3)
The First Targeted Therapy to Treat Cancer: The Tamoxifen Tale (2018) (3)
Telling details of breast-cancer recurrence (2018) (3)
By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy (2008) (3)
Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer? (1996) (3)
Design of an ideal hormone replacement therapy for women. (1996) (3)
Advances in endocrine therapy for the treatment and prevention of breast cancer. (2003) (3)
Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. (2003) (3)
Chemoprevention in the 21st century: is a balance best or should women have no estrogen at all? (2005) (3)
Towards an Optimal Strategy for the Adjuvant Therapy of Breast Cancer (1986) (3)
Award Lecture Evolution of long-term adjuvant anti-hormone therapy: Consequences and opportunities (2011) (3)
An Introduction to the Regulation of Sex Steroids for the Treatment of Cancer (2009) (3)
Future directions in endocrine therapy for the treatment and prevention of breast cancer (2000) (3)
Oestrogen and Anti-Oestrogen Action: A Hypothesis for the Regulation of Breast Cancer Cell Replication (1986) (3)
Tamoxifen and Other Antiestrogens in Prevention and Therapy of Breast Cancer (2000) (3)
Abstract 2332: Integral modulation of nuclear factor-kappa B activation by C/EBPβ and the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in estrogen-deprived breast cancer cells (2017) (3)
'Who do you think you are?'. (2014) (3)
A new day dawns: women without oestrogen or is a balance best? (2002) (3)
The 4Ps of Breast Cancer Chemoprevention: Putting Proven Principles into Practice (2017) (3)
SERMs : meeting the promise of multifunctional medicines. (Commentary) (2007) (3)
Chemoprevention of breast cancer. (2004) (3)
Laboratory evidence to support the use of long-term adjuvant tamoxifen therapy for breast cancer. (1989) (3)
Estrogen Action and Breast Cancer (2000) (2)
DIETHYLSTILBESTROL: A TRAGEDY IN REPRODUCTIVE ENDOCRINOLOGY BUT A PIONEERING CANCER TREATMENT (2013) (2)
Antiestrogens: Clinical Applications of Pharmacology (2000) (2)
Receptor Antiestrogen EM-800 ( SC 5705 ) with the Human Estrogen The Interaction of Raloxifene and the Active Metabolite of the Updated Version (1999) (2)
Carcinogenesis and Tamoxifen (2013) (2)
Metabolism of tamoxifen in rats and mice a comparison with patients undergoing breast cancer therapy (1988) (2)
Corrigendum: Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague rats (Carcinogenesis (1996) 17 (1051-1056)) (1996) (2)
Targeted hormone therapy for breast cancer. (1993) (2)
Repurposing failed pharmaceuticals as the first targeted medicines for the treatment and prevention of breast cancer (2014) (2)
Tamoxifen to prevent breast cancer. (2000) (2)
The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model (2004) (2)
Hormonal Therapy for Breast Cancer (2005) (2)
Abstract 474: Estrogen-responsive miRNAs as modulators of E2-induced apoptosis in AI-resistant breast cancer (2017) (2)
A comparative study of antiestrogenS LY156758 and tamoxifen in N-nitrosomethylurea-induced rat mammary carcinomas: A POTENTIAL MODEL for adjuvant therapy (1984) (2)
8.09 – Raloxifene (2007) (2)
TAMOXIFEN AND ENDOMETRIAL CANCER (1988) (2)
Identification of an estrogenic metabolite of tamoxifen during high-dose therapy for breast cancer (1981) (2)
Abstract 956: The liver-X-receptor-α is involved in the induction by Tamoxifen of breast cancer cell differentiation and death (2012) (2)
Activated Estrogens and Antiestrogens: A 30-Year Journey with David Kupfer (2006) (2)
Abstract 3432: Evolving genomes of breast cancer aromatase inhibitor resistance models (2018) (2)
Telling details of breast-cancer recurrence. (2018) (2)
Moving Precision Oncology Forward Amid Myths and Misconceptions. (2018) (2)
Estrogen Receptor Pathways and Breast Cancer (2008) (2)
Contrasting subcellular responses to monohydroxytamoxifen and oestradiol benzoate in the immature rat uterus [proceedings]. (1978) (2)
Control of experimental breast cancer by antioestrogenic therapies [proceedings]. (1979) (2)
Abstract 5682: Modeling the pharmacological importance of endoxifen for the treatment of ER-positive breast cancer in premenopausal patients (2012) (2)
New Molecular Probes to Assess Estrogen and Antiestrogen Actions (1987) (2)
Adjuvant Therapy: The Breakthrough (2013) (1)
New strategies for the treatment of breast cancer (2001) (1)
Pharmacology and Use of Antiestrogens in Treatment and Chemoprevention of Breast Cancer (1999) (1)
Recent Progress in Breast Cancer Research (2009) (1)
Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer. (2017) (1)
Anti-oestrogenic activity in compounds related to ethamoxytriphetol (MER 25), clomiphene and MRL 37. (1973) (1)
Estrogen for the Treatment and Prevention of Breast Cancer (2022) (1)
Erratum: Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene (Expert Opinion on Pharmacotherapy (2011) 12: 4 (657-674)) (2012) (1)
Breast-Cancer Prevention with Antiestrogens (2009) (1)
A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible? (2008) (1)
Tamoxifen Decreases Mortality, but How? (2017) (1)
The forgotten group at risk for breast cancer. (1990) (1)
Drug Resistance to Antioestrogen Therapy (1994) (1)
CLUES ABOUT ESTROGEN AND ANTIESTROGEN ACTION FROM X-RAY CRYSTALLOGRAPHY (2013) (1)
Oestrogen is bad for patients with breast cancer? (2007) (1)
Gene Expression Profiles with Activation of the Estrogen Receptor-Selective Estrogen Receptor Modulator Complex in Breast Cancer Cells Expressing Wild-Type Estrogen Receptor 1 (2002) (1)
Celebrating an illustrious career in breast cancer research, SERMS and mentorship (2017) (1)
Chemoprevention: Cinderella Waiting for the Ball (2013) (1)
Introduction to a special edition in Steroids of nuclear hormone receptor modulators (2014) (1)
Abstract P2-13-09: Pharmacological impact of endoxifen in a laboratory simulation of tamoxifen therapy in postmenopausal breast cancer patients (2012) (1)
The quest for multi-functional medicines: path for progress: the tamoxifen story (2011) (1)
William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy. (1993) (1)
Serendipity in the search for "morning-after pills" led to clomiphene for the induction of ovulation. (2020) (1)
Effects of ICI 182,780 on tamoxifen-stimulated breast and endometrial cancer (2001) (1)
112 Effects of estradiol on components of the plasminogen-plasmin system in MDA-MB-231 breast cancer cells stably transfected with the estrogen receptor (1997) (1)
Overexpression of MCT1 oncogene contributes to increased tumorigenicity of MCF7 breast cancer cells (2005) (1)
Progesterone and Synthetic Progestin Controversies. (2015) (1)
Antioestrogenic derivatives of nafoxidine stimulate progesterone receptor synthesis in vivo [proceedings]. (1980) (1)
Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46474) in the rat. (1977) (1)
Steroid receptors in breast cancer (2018) (1)
Characteristics of raloxifene-stimulated breast tumors in vivo (2001) (1)
A life in breast cancer research: tamoxifen, SERMs and the unique paired-biology of the unfolded protein response and apoptosis (2019) (1)
Node-negative breast cancer: tamoxifen and chemosuppression. (1990) (1)
Target Site Specificity of Tamoxifen: A Balance of Estrogenic and Antiestrogenic Properties (1987) (1)
The Role of Prolonged Antihormonal Treatment of Breast Cancer: A Strategy for Adjuvant Therapy (1991) (1)
Induction of ovulation by nonsteroidal antiestrogens (2013) (1)
Tamoxifen for the Treatment of Breast Cancer (2009) (1)
Angela M.H. Brodie, PhD, FAACR: In Memoriam (1934–2017) (2017) (1)
Original article Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients (2007) (1)
8.08 – Tamoxifen (2007) (1)
Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines (2016) (1)
Targeted antiestrogens. (1997) (1)
Is There a Role for Raloxifene and Tamoxifen for the Prevention of Breast Cancer (2016) (1)
RESPONSE: Re: Medroxyprogesterone Acetate and Metastases: Of Mice and (Wo)Men (2005) (1)
Antiestrogen therapy for breast cancer: current strategies and potential causes for therapeutic failure. (1991) (1)
IV.7 Tamoxifen and uterine cancer: Confounding variables (1998) (1)
Tamoxifen Goes Forward Alone (2013) (1)
Role of Protein Translation in Unfolded Protein Response (2019) (1)
Prelude to breast cancer prevention with an antiestrogen. (1990) (1)
Modulation of nuclear oestrogen receptor levels by oestrogen and antioestrogen [proceedings]. (1980) (1)
The influence of tumor proliferation and treatment time on growth delay in human breast tumor xenografts treated with fractionated radiation (1993) (1)
Estrogen Deprivation Therapy in Ovarian Cancer: An Opportunity. (2016) (1)
Cross-resistance of tamoxifen and raloxifene on the growth of raloxifene-resistant breast cancer cells in vivo and in vitro (2001) (1)
Antiestrogens: Past, Present, and Future (1997) (1)
PHARMACOGENOMICS OF TAMOXIFEN (2013) (0)
Correction to: Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis (2018) (0)
Robertson JFR, Nicholson RI, Hayes DF:Endocrine Therapy of Breast Cancer. London, UK: Martin Dunitz; 2002. 296pp. (2003) (0)
A quiet revolution in the endocrine therapy of breast cancer (2003) (0)
Correction to: Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis (2018) (0)
ASO Author Reflections: An Optimal Biological Model for Successful Drug Discovery (2019) (0)
The Science of Selective Estrogen Receptor Modulators : Concept to Clinical Practice 55 (2006) (0)
Insights into the Molecular Mechanism of SERMs Through New Laboratory Models (2002) (0)
How PERK kinase conveys stress signals to nuclear factor-κB to mediate estrogen-induced apoptosis in breast cancer cells? (2018) (0)
Update on tamoxifen, raloxifene, and breast cancer (1999) (0)
Abstract 1689: Comparative whole genome analyses of breast cancer aromatase inhibitor resistance models (2019) (0)
A New Therapeutic Paradigm for Breast Cancer Exploiting Low Dose Estrogen-Induced Apoptosis (2007) (0)
Breast cancer prevention: Selective estrogen receptor modulators (2003) (0)
[Effect of tamoxifen on estrogen-stimulated growth of MCF-7 tumors in athymic mice: preliminary report]. (1990) (0)
Estrogen Receptor Complex to Trigger or Delay Estrogen-Induced Apoptosis in Long-Term Estrogen Deprived Breast Cancer (2022) (0)
Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells (2018) (0)
Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death (2016) (0)
Co-expression of ER and c-erb B2 in breast cancer (2001) (0)
Metabolites of Tamoxifen as the Basis of Drug Development (2013) (0)
Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with Z2OHTPE and a glucocorticoid receptor-interacting protein 1 NR box II peptide (2019) (0)
Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with Ethoxytriphenylethylene and GRIP Peptide (2017) (0)
Binding affinity of the nonsteroidal antiestrogens tamoxifen and mono-hydroxytamoxifen for the estrogen receptor from chick liver nuclei (1980) (0)
5 Antiestrogens in Cancer Treatment1 (1988) (0)
Hormones and cancer (2019) (0)
Reduced antioestrogenic activity in derivatives of tamoxifen unable to undergo metabolic p-hydroxylation [proceedings]. (1980) (0)
Safety of tamoxifen (1994) (0)
Estrogen-Induced Apoptosis in Breast Cancer Cells: Translation to Clinical Relevance (2012) (0)
Changes in lipid metabolism by tamoxifen (1999) (0)
Abstract #4606: Bazedoxifene (TSE-424) is a potent inhibitor of long-term estrogen deprived breast cancer cells (2009) (0)
Abstract #2338: 17-\#946; Estradiol impairs the growth of selective estrogen receptor modulator (SERM)-resistant endometrial tumors (2009) (0)
How long should adjuvant tamoxifen be continued? Commentary I (1994) (0)
COMMENTARY Antiestrogenic Action of Raloxifene and Tamoxifen: Today and Tomorrow (1998) (0)
The Legacy of Tamoxifen (2013) (0)
Histopathology of rat mammary cancer and correlation with treatment response (1981) (0)
Robertson JFR, Nicholson RI, Hayes DF:Endocrine Therapy of Breast Cancer. London, UK: Martin Dunitz; 2002. 296pp. (2003) (0)
COMMENT ON : EFFECTS OF THE ANTIESTROGENS TAMOXIFEN, TOREMIFENE, AND ICI 182,780 ON ENDOMETRIAL CANCER GROWTH. AUTHORS' REPLY (1999) (0)
130. Comparison of the effects of tantoxifen and monohydroxytamoxifen in the rat uterus and mammary gland (1978) (0)
Assessing the safety of hormonal replacement therapy (2016) (0)
Abstract 5597: Modulating therapeutic effects of c-Src inhibitor via estrogen receptor and HER2 in breast cancer cell lines (2012) (0)
Tamoxifen and Raloxifene Head to Head: The STAR Trial (2013) (0)
The estrogen receptor (ER) as a novel target for therapeutics in breast cancer cell refractory to antihormone therapy (2004) (0)
Abstract 144: Genome-wide DNA methylation changes in AI-resistant breast cancer models during E2-treatment (2020) (0)
Breast cancer prevention trumps cure (2017) (0)
Estrogen Activity in Plastic Products: Yang et al. Respond (2011) (0)
Steroid Receptors and Selective Estrogen Receptor Modulation in Mammary and Gynecologic Malignancy (2009) (0)
Abstract P4-02-12: Genomic Evolution of Endocrine-Resistant Breast Cancer Cell Lines Reveals Molecular Aberrations Consistent with Biological Phenotype (2010) (0)
Book Review Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs Edited by Antonio Cano Sanchez, Joaquim Calaf i Alsina, and José-Luis Dueñas-Díez. 357 pp., illustrated. Berlin, Springer, 2006. $169. 978-3-540-24227-7 (2007) (0)
RESPONSE (2000) (0)
Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene (2012) (0)
Long-term tamoxifen therapy of athymic mice implanted with MCF-7 tumors: Tumoristatic action and complete antiestrogenic action in the moose uterus (1987) (0)
Variant in Athymic Mice by Novel Steroidal Antiestrogens Inhibition of Tamoxifen-stimulated Growth of an MCF-7 Tumor Updated (2006) (0)
Abstract 1073: Modulation of aromatase inhibitor resistance by miRNAs in breast cancer (2016) (0)
Abstract 607: Loss of pigment epithelium derived-factor (PEDF) is associated with breast cancer progression and antihormone drug resistance (2010) (0)
The function of membrane-associated molecules in acquired resistance to antiestrogens in breast cancer (2015) (0)
Editorial: A therapeutic withdrawal can make a strategic advance (1992) (0)
Abstract 2939: Novel molecular mechanism for estradiol-induced apoptosis that contrasts with cytotoxic chemotherapy-induced apoptosis in breast cancer. (2013) (0)
Role of estrogen receptor(ER)β in modulating ERα SERM complexes in MDA-MB-231 breast cancer cells (2001) (0)
Abstract 3924: Alteration of the shape of the ligand estrogen receptor complex controls estrogen induced apoptosis in breast cancer (2012) (0)
Monoclonal antibody recognition of [3H]monohydroxytamoxifen-receptor and 125I-estradiol-receptor complex in ovarian epithelial carcinoma (1983) (0)
Oral pure antiestrogens as a solution to acquired drug resistance to aromatase inhibitors (2015) (0)
Relevance of metabolic activation for the antihormone activity of tamoxifen (1979) (0)
Antiestrogens Old and New: The Search for a Non-Toxic Agent with No Estrogenic Properties (1987) (0)
Long-Term Tamoxifen Therapy: An Appropriate Chemosuppressive Treatment for Breast Cancer (1990) (0)
Discovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens (2013) (0)
Chemoprevention in British women is inadequate (2017) (0)
Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G 0 / G 1 cell cycle arrest in SKBr 3 breast cancer cells (0)
Hormone replacement therapy and women’s health (2013) (0)
Is over-expression of protein kinase C alpha required to induce a hormone-independent phenotype in T47D breast cancer cells? (2001) (0)
Abstract 2921: Critical mediation of E2-induced apoptosis through c-Src in long-term estrogen deprived breast cancer cells (2012) (0)
ADJUVANT ANTIHORMONE THERAPY (2013) (0)
Control of experimental breast cancer by antioestrogenic therapies [proceedings]. (1979) (0)
- Nitrosomethylurea-induced Rat Mammary Carcinoma Model N Antitumor Actions of Keoxifene and Tamoxifen in the Updated Version (2006) (0)
Abstract 955: Role of cMYC as a critical determinant of estrogen-independent growth of estrogen deprivation-resistant breast cancer cells (2012) (0)
Abstract 5642: Transcriptional deregulation of cMYC as a critical determinant of estrogen independence and aromatase inhibitor resistance in breast cancers. (2013) (0)
Hormones: edited by Anthony W. Norman and Gerald Litwack, Academic Press, 1987. $49,95 (xv + 806 pages) ISBN 0 12 5214405 (1988) (0)
Abstract 2291: Inhibition of c-Src restores estrogen stimulated growth in estrogen-deprivation resistant MCF-7 breast cancer cells (2011) (0)
Estrogen Receptor Alpha Ligand Binding Domain Y537S in Complex with TTC-352 and GRIP Peptide (2020) (0)
Do All Roads Lead to the Oestrogen Receptor (1992) (0)
Hormone receptors, present and future (2003) (0)
Molecular, Cellular, and Systemic Mechanisms of Antiestrogen Action (1996) (0)
Targeted therapies: Any surprises from selective oestrogen-receptor modulators? (2013) (0)
Comment on: Medroxyprogesterone acetate and metastases : Of mice and (Wo)men. Author's reply (2005) (0)
The journal of steroid biochemistry and molecular biology addresses (1992) (0)
ASO Author Reflections: An Optimal Biological Model for Successful Drug Discovery (2019) (0)
Small Molecule Therapeutics Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer (2014) (0)
Anti-estrogens and selective estrogen-receptor modulators (2015) (0)
Abstract 830: Transcriptional modulation of estrogen-induced apoptosis through activation of c-Fos/c-Jun in long-term estrogen deprived breast cancer cells. (2013) (0)
Abstract 2863: Mechanisms underlying estrogen-induced inflammation in estrogen-deprived breast cancer cells (2016) (0)
The search for antiestrogens (2008) (0)
Tamoxifen for the Treatment of Breast Cancer in the Premenopausal Patient (1992) (0)
CHEMOTHERAPY. PROC. 9TH INT. CONGR. CHEMOTHER. VOLUME 7. CANCER CHEMOTHERAPY (1976) (0)
P05 16 SP – THE EFFECT OF MONOHYDROXYTAMOXIFEN ON THE RADIOSENSITIVITY OF THE HUMAN BREAST CANCER CELL LINE, MCF-7 (1991) (0)
Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with 3OHTPE and GRIP Peptide (2019) (0)
Abstract 609: Paradoxical actions of a c-Src inhibitor on estradiol-induced apoptosis in long-term estrogen deprivation breast cancer cells (2010) (0)
Endocrine Therapy for Hormone Receptor‐Positive Breast Cancer (2019) (0)
Receptor in Breast Cancer Cells Expressing Wild-Type Estrogen-Selective Estrogen Receptor Modulator Complex α Receptor Gene Expression Profiles with Activation of the Estrogen (2002) (0)
EDITORIALS Tamoxifen and Tumorigenicity: a Predictable Concern (1995) (0)
V.3 Is there life after tamoxifen? New anti-oestrogens (1998) (0)
Prevention of breast cancer (2006) (0)
Biology of SERMs and strategies for use (1998) (0)
Practical Progress in the Chemoprevention of Breast Cancer with Selective Estrogen Receptor Modulators (2008) (0)
Abstract 4409: The characterization of isomerically stable fixed ring derivatives of tamoxifen metabolites 4-hydroxytamoxifen and 4-hydroxy-N-desmethyltamoxifen (endoxifen) in vitro. (2013) (0)
Cancer chemoprevention at the crossroads (2015) (0)
Acquired Resistance to Tamoxifen: Back to the Beginning (2013) (0)
MOLECULAR PHARMACOLOGY OF TAMOXIFEN; AN ANTIESTROGEN WITH ANTITUMOR PROPERTIES IN ANIMALS AND MAN (2011) (0)
Tamoxifen, raloxifene and selective estrogen receptor modulators to estrogen-induced apoptosis, one thing led to another (2015) (0)
Activated Estrogens and Antiestrogens: A 30-Year Journey with David Kupfer (2006) (0)
Letter the editor (multiple letters) (2000) (0)
92103997 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer (1992) (0)
Design of an ideal hormone replacement therapy for women (1996) (0)
Molecular Classification of Estrogens 1 (2001) (0)
ORAL CONTRACEPTIVES AND WOMEN'S HEALTH (2013) (0)
Abstract P3-05-11: The evolution of the estrogen receptor (ER) complex conformation governs estrogen-induced apoptosis in antihormone-resistant breast cancer cells (2016) (0)
The Wisconsin Story in the 1980s: Discovery of Target Site-Specific Estrogen Action (2013) (0)
Abstract 5633: Unique modulation of estrogen-induced apoptosis with structural analogues of endoxifen in long-term estrogen-deprived (LTED) breast cancer cells (2017) (0)
A quiet revolution in the endocrine therapy of breast cancer (2003) (0)
Drug Resistance to Antiestrogens (2009) (0)
Abstract 828: Mechanisms underlying differential response to estrogen-induced apoptosis in long-term estrogen-deprived breast cancer cell lines. (2013) (0)
Comparative metabolism of tamoxifen in mice, rats, and chickens (1984) (0)
Tamoxifen may prove successful in long-term cancer prevention (1991) (0)
Comment on: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. Authors' reply (2003) (0)
The evolving role of endocrine therapy for the treatment and prevention of breast cancer. (2002) (0)
Differing Perspectives on Breast Cancer Chemoprevention. (2016) (0)
Paradoxical action of antiestrogens in vivo and in vitro in the murine uterus (1984) (0)
SERMS (Selective Estrogen Receptor Modulators) (2004) (0)
Adapting to change and seeing the opportunities in breast cancer management (2012) (0)
Molecular Biology of Breast Neoplasia (2004) (0)
90244353 Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer (1991) (0)
Are we giving tamoxifen for too long? (1991) (0)
Tamoxifen's patenting problems in America, which created a “cancer treatment company” (2022) (0)
Special Lecture Development of Antiestrogens and Their Use in Breast Cancer : Eighth Cain Memorial Award Lecture 1 (2006) (0)
Targeting the estrogen receptor to treat and prevent breast cancer (2005) (0)
204. Substrate-Mediated Gene Delivery for Assessment of Signal Transduction Pathways in Cancer Cells (2005) (0)
Tumoristatic actions of antiestrogens in breast cancer (1990) (0)
Unexpected oestrogenic activity in a derivative of antioestrogenic triphenylethylenes (1984) (0)
Laboratory Studies on the Mode of Action and Application of Antiestrogen for Breast Cancer Therapy (1988) (0)
Abstract 1279: Caspase-4 is critical in estrogen-induced apoptosis in antihormone-resistant breast cancer (2010) (0)
Toremifene as an anticancer agent. (1990) (0)
HEALTH AND SAFETY INSPECTIONS (1977) (0)
S26 The molecular biology of the estrogen receptor (ER) aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene (1998) (0)
Chemoprevention of Cancer (1999) (0)
Forward to the Fox Chase Cancer Center in Philadelphia (2022) (0)
A CENTURY OF DECIPHERING THE CONTROL MECHANISMS OF ESTROGEN ACTION IN BREAST CANCER: THE ORIGINS OF TARGETED THERAPY AND CHEMOPREVENTION (2013) (0)
Cellular Arrays (US Patent Application) (2008) (0)
Understanding the New Biology of Estrogen-Induced Apoptosis and Its Application in Patient Care (2015) (0)
Successful translation research with selective oestrogen receptor modulators to treat and prevent breast cancer (2007) (0)
RESPONSE: Re: Playing the Old Piano: Another Tune for Endocrine Therapy (2004) (0)
S37 Endocrine Therapies in the Future: Will an Old Dog Learn New Tricks? (2005) (0)
Positive Breast Cancer Cells − of Estrogen Receptor Coupled Receptor GPR 30 Inhibits Proliferation − (2010) (0)
Targeting estrogen to kill ER-positive and ER-negative breast cancer (2005) (0)
Legislation and hospitals. (1971) (0)
therapy in epithelial and sex-cord stroma ovarian cancers represent an intriguing and promising area of research. (2016) (0)
Fundamentals of endocrinology: W. Roy Slaunwhite Jr, Marcel Dekker, 1988. $45.00 (USA and Canada) $54.00 (elsewhere) (xiii + 422 pages) ISBN 0 8247 7714 X (1988) (0)
A Raloxifene Withdrawal Response (2016) (0)
Antihormonal Therapy for Breast and Prostate Cancer (2007) (0)
Chemoprevention of cancer : a clinical update (1999) (0)
Practical advances in biodiagnosis and biomodulation for the medical oncologist. Abstracts from the conference of the Chemotherapy Foundation. November 9-10, 1989, New York City, USA. (1990) (0)
Preventing breast cancer with tamoxifen. (1998) (0)
Brodie [née Hartley], Angela Mary (1934–2017), cancer research scientist (2021) (0)
Targeted Therapy and Chemoprevention Steroid Action in Breast and Prostate Cancer: The Origins of A Century of Deciphering the Control Mechanisms of Sex (2009) (0)
Tumoristatic action of tamoxifen: experimental evidence for clinical application in stage I and II breast cancer. (1989) (0)
Two antiestrogenic strategies to treat breast cancer at the Worcester Foundation (2022) (0)
In postmenopausal women with breast cancer, switching to exemestane increased disease-free survival compared to continuing tamoxifen (2005) (0)
Selective estrogen receptor modulators as a new postmenopausal prevention- maintenance therapy (2020) (0)
A STAR is born: Raloxifene is the winner for the chemoprevention of breast cancer (2006) (0)
Benefits of Tamoxifen Outweigh Endometrial Cancer Risk (1996) (0)
A17 The development of a new strategy to prevent diseases of the menopause in postmenopausal women (1996) (0)
The quest for multi-functional medicines: path for progress: the SERM story (2011) (0)
S29 Optimizing treatment and prevention of breast cancer: Time for a change? (2007) (0)
A new strategy: long-term adjuvant tamoxifen treatment and other discoveries at the University of Leeds (2022) (0)
170. Transfected Cell Arrays for Assessment of Estrogen Receptor Activation in Breast Cancer Cells (2006) (0)
The Foundation of Current “Antiestrogenic” Strategies to Treat Breast Cancer: A Personal Perspective (1996) (0)

This paper list is powered by the following services:

Other Resources About V. Craig Jordan

en.wikipedia.org

What Schools Are Affiliated With V. Craig Jordan?

V. Craig Jordan is affiliated with the following schools:

V. Craig Jordan's Academic­Influence.com Rankings